[PDF][PDF] Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
HS Friedman, MD Prados, PY Wen… - Journal of clinical …, 2009 - researchgate.net
… In addition to meeting MRI criteria for complete response, a patient could not be taking
corticosteroids greater than physiologic levels (ie, equivalent to 20 mg/d hydrocortisone) at …
corticosteroids greater than physiologic levels (ie, equivalent to 20 mg/d hydrocortisone) at …
[HTML][HTML] Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
…, MS Berger, SM Chang, MD Prados… - … England Journal of …, 2015 - Mass Medical Soc
Background The prediction of clinical behavior, response to therapy, and outcome of infiltrative
glioma is challenging. On the basis of previous studies of tumor biology, we defined five …
glioma is challenging. On the basis of previous studies of tumor biology, we defined five …
[PDF][PDF] Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
…, KR Lamborn, SM Chang, MD Prados… - Journal of Clinical …, 2008 - researchgate.net
… (D) Patients with a greater percentage of tumor resection had a significantly longer
overall survival (Cox proportional hazards model P … Cavaliere R, Lopes MB, Schiff D: Low-grade …
overall survival (Cox proportional hazards model P … Cavaliere R, Lopes MB, Schiff D: Low-grade …
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
…, KA Jaeckle, AP Kyritsis, MD Prados… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: To determine aggregate outcomes and prognostic covariates in patients with
recurrent glioma enrolled onto phase II chemotherapy trials. PATIENTS AND METHODS: …
recurrent glioma enrolled onto phase II chemotherapy trials. PATIENTS AND METHODS: …
[PDF][PDF] Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
WKA Yung, MD Prados, R Yaya-Tur… - Journal of Clinical …, 1999 - Citeseer
Purpose: To determine the antitumor efficacy and safety profile of temozolomide in patients
with malignant astrocytoma at first relapse. Patients and Methods: This open-label, …
with malignant astrocytoma at first relapse. Patients and Methods: This open-label, …
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis
KR Lamborn, SM Chang, MD Prados - Neuro-oncology, 2004 - academic.oup.com
Survival for patients with glioblastoma multiforme is short, and current treatments provide
limited benefit. Therefore, there is interest in conducting phase 2 trials of experimental …
limited benefit. Therefore, there is interest in conducting phase 2 trials of experimental …
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost±hyperthermia for glioblastoma multiforme
…, CJ Diederich, KR Lamborn, MD Prados… - International Journal of …, 1998 - Elsevier
Purpose: To determine if adjnvant interstitial hyperthennia (HT) significantly improves survival
of patients with moma undergoing hrachytherapy boost after conventional radiotherapy. …
of patients with moma undergoing hrachytherapy boost after conventional radiotherapy. …
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
…, R Kaplan, AJ Murgo, C Stiles, MD Prados - Clinical Cancer …, 2006 - AACR
Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics
of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-…
of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-…
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan, MD Prados, T Tihan… - Journal of the …, 2005 - academic.oup.com
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …
[HTML][HTML] Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
…, PL Nghiemphu, CD James, MD Prados… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1 R132MUT) is frequent
in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a …
in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a …
